Baijin Life Science Holdings Limited (HKG:1466)

HKG:1466 Revenue

Baijin Life Science Holdings had revenue of 55.15M HKD in the half year ending September 30, 2025, with 119.52% growth. This brings the company's revenue in the last twelve months to 119.80M, up 20.46% year-over-year. In the fiscal year ending March 31, 2025, Baijin Life Science Holdings had annual revenue of 135.56M with 152.54% growth.

• Revenue (ttm): 119.80M
• Revenue Growth: +20.46%
• P/S Ratio: 4.20
• Revenue / Employee: 1.52M
• Employees: 79
• Market Cap: 503.42M

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2025	135.56M	81.88M	152.54%
Mar 31, 2024	53.68M	-33.20M	-38.22%
Mar 31, 2023	86.88M	24.23M	38.68%
Mar 31, 2022	62.65M	19.32M	44.60%
Mar 31, 2021	43.32M	-68.65M	-61.31%